431 related articles for article (PubMed ID: 31646557)
1. FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway.
Liu FH; Cui YP; He YK; Shu RH
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8265-8273. PubMed ID: 31646557
[TBL] [Abstract][Full Text] [Related]
2. LncRNA HOTAIRM1 inhibits the progression of hepatocellular carcinoma by inhibiting the Wnt signaling pathway.
Zhang Y; Mi L; Xuan Y; Gao C; Wang YH; Ming HX; Liu J
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4861-4868. PubMed ID: 30070317
[TBL] [Abstract][Full Text] [Related]
3. miRNA-217 inhibits proliferation of hepatocellular carcinoma cells by regulating KLF5.
Gao W; Lu YX; Wang F; Sun J; Bian JX; Wu HY
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7874-7883. PubMed ID: 31599412
[TBL] [Abstract][Full Text] [Related]
4. LncRNA TP73-AS1 promotes malignant progression of hepatoma by regulating microRNA-103.
Ma CX; Gao WC; Tian L
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4713-4722. PubMed ID: 31210297
[TBL] [Abstract][Full Text] [Related]
5. STYXL1 promotes malignant progression of hepatocellular carcinoma via downregulating CELF2 through the PI3K/Akt pathway.
Wu JZ; Jiang N; Lin JM; Liu X
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2977-2985. PubMed ID: 32271415
[TBL] [Abstract][Full Text] [Related]
6. LncRNA MT1JP inhibits the malignant progression of hepatocellular carcinoma through regulating AKT.
Wu JH; Xu K; Liu JH; Du LL; Li XS; Su YM; Liu JC
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6647-6656. PubMed ID: 32633354
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway.
Fang D; Wang MR; Guan JL; Han YY; Sheng JQ; Tian DA; Li PY
Exp Cell Res; 2021 Sep; 406(2):112727. PubMed ID: 34370992
[TBL] [Abstract][Full Text] [Related]
8. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
[TBL] [Abstract][Full Text] [Related]
9. USP25 promotes hepatocellular carcinoma progression by interacting with TRIM21 via the Wnt/β-catenin signaling pathway.
Liu Y; Ma J; Lu S; He P; Dong W
Chin Med J (Engl); 2023 Sep; 136(18):2229-2242. PubMed ID: 37439386
[TBL] [Abstract][Full Text] [Related]
10. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
Lei T; Zhu X; Zhu K; Jia F; Li S
Cancer Biol Ther; 2019; 20(7):1007-1016. PubMed ID: 30929558
[TBL] [Abstract][Full Text] [Related]
11. Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway.
Zheng Y; Jiang L; Hu Y; Xiao C; Xu N; Zhou J; Zhou X
BMC Cancer; 2017 Feb; 17(1):161. PubMed ID: 28241806
[TBL] [Abstract][Full Text] [Related]
12. Autophagy promotes metastasis and glycolysis by upregulating MCT1 expression and Wnt/β-catenin signaling pathway activation in hepatocellular carcinoma cells.
Fan Q; Yang L; Zhang X; Ma Y; Li Y; Dong L; Zong Z; Hua X; Su D; Li H; Liu J
J Exp Clin Cancer Res; 2018 Jan; 37(1):9. PubMed ID: 29351758
[TBL] [Abstract][Full Text] [Related]
13. EGFL7 promotes hepatocellular carcinoma cell proliferation and inhibits cell apoptosis through increasing CKS2 expression by activating Wnt/β-catenin signaling.
Li Z; Xue TQ; Yang C; Wang YL; Zhu XL; Ni CF
J Cell Biochem; 2018 Dec; 119(12):10327-10337. PubMed ID: 30129142
[TBL] [Abstract][Full Text] [Related]
14. MIIP inhibits malignant progression of hepatocellular carcinoma through regulating AKT.
Fang J; Chen YL; Yao HB; Peng SS; Yang P; Ding ZY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2335-2346. PubMed ID: 32196585
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MINCR promotes the development of liver cancer by regulating microRNA-107/β-catenin.
Li H; Yuan R; Wang H; Li C; Wei J
J BUON; 2020; 25(2):972-980. PubMed ID: 32521894
[TBL] [Abstract][Full Text] [Related]
16. LncRNA H19 promotes the development of hepatitis B related hepatocellular carcinoma through regulating microRNA-22 via EMT pathway.
Li L; Han T; Liu K; Lei CG; Wang ZC; Shi GJ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5392-5401. PubMed ID: 31298392
[TBL] [Abstract][Full Text] [Related]
17. LRP16 prevents hepatocellular carcinoma progression through regulation of Wnt/β-catenin signaling.
Shao L; Jing W; Wang L; Pan F; Wu L; Zhang L; Yang P; Hu M; Fan K
J Mol Med (Berl); 2018 Jun; 96(6):547-558. PubMed ID: 29748698
[TBL] [Abstract][Full Text] [Related]
18. ATDC promotes the growth and invasion of hepatocellular carcinoma cells by modulating GSK-3β/Wnt/β-catenin signalling.
Li W; Xue H; Li Y; Li P; Ma F; Liu M; Kong S
Clin Exp Pharmacol Physiol; 2019 Sep; 46(9):845-853. PubMed ID: 31168819
[TBL] [Abstract][Full Text] [Related]
19. Nek2B accelerates the progression of hepatocellular carcinoma through regulating SFRP1 to activate the Wnt/β-catenin pathway.
Li L; Ye Y; Ran Y; Zhou Y; Dang Z; Su X; Hu S
J BUON; 2021; 26(3):861-867. PubMed ID: 34268946
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-30a-3p inhibits malignant progression of hepatocellular carcinoma through regulating IGF1.
Wei YY; Ren TL
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12144-12152. PubMed ID: 33336732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
